Data on Merck & Co., Inc. (MRK)’s Pembrolizumab From Largest Study To Date Of Investigational Anti-PD-1 Antibody In Advanced Melanoma Highlighted At American Society of Clinical Oncology 2014
6/2/2014 8:55:29 AM
CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from the company’s large ongoing Phase 1b study (KEYNOTE-001) evaluating pembrolizumab (MK-3475), Merck’s investigational anti-PD-1 antibody, as a single agent (monotherapy) in 411 patients with advanced melanoma. Following treatment with pembrolizumab, the estimated overall survival (OS) rate at one year was 69 percent across all patients studied, including 74 percent in patients without prior ipilimumab therapy (current standard therapy) and 65 percent in patients who had progressive disease on or following ipilimumab. At 18 months, the estimated OS was 62 percent. The median OS has not been reached, with some patients receiving treatment with pembrolizumab as monotherapy for more than two years.
Help employers find you! Check out all the jobs and post your resume.
comments powered by